Salarius Pharmaceuticals Q3 EPS $(0.73) Down From $(0.15) YoY, Grant Sales $874.949M Up From $469.051M YoY

Salarius Pharmaceuticals (NASDAQ:SLRX) reported quarterly losses of $(0.73) per share. This is a 386.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $874.949

Benzinga · 11/13/2019 13:07

Salarius Pharmaceuticals (NASDAQ:SLRX) reported quarterly losses of $(0.73) per share. This is a 386.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $874.949 million in sales this quarter. This is a 86.54 percent increase over sales of $469.051 million the same period last year.